somatoform disorder
Conditions
Interventions
control group:Escitalopram treatment
study group B(hi-frequency stimulus group):10Hz rTMS plus Escitalopram treatment
study group C(low-frequency stimulus group):1Hz rTMS plus Escitalopram treatment
Sponsors
Affiliated mental health center, Tongji Medical College of Huazhong University of Science and Technology (HUST)
Eligibility
Sex/Gender
Female
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. in accordance with the somatoform disorders defined in Diagnostic and Statistical Manual of Mental Disorders DSM-IV; 2. female aged 18 to 65 years; 3. dextromanual; 4. education on the junior level or above.
Exclusion criteria
Exclusion criteria: 1. women in the gestaional or breast feeding period, women of child-bearing age and showing positive in pregnancy test; 2. be afflicted with other psychiatric illnesses besides somatoform disorders according to DSM-? standards, including: schizaphrenia schizo affective psychosis, depressive disorders, mental retardation, and psychiatric illnesses relative to dementia; 3. with a history of epilepsia or brain physical illnesses or complication, or a history of alcohol or drug dependency; 4. with serious or instable physical illnesses; 5. BMI35; 6. no significant alleviation of somatoform disorders after full use of the anti-depressive medicines of at the least 2 kinds and after whole-course treatments within the latest two years; 7. unsatisfactory result after full use of Escitalopram and after whole-course treatments; 8. have taken Escitalopram within the latest month; 9. allergic to Escitalopram; 10. have been treated with electrical shock in 2 months before the baseline. Removal criteria: (1) patients not as to the criteria yet included by mistake; (2) fail to take medicines or receive rTMS treatment as required; (3) of whom the judgement data or the observation index were not collected completely during the test; (4) during the interference the patients have recieved other unconcerned medical or non-medical treatment which might affect the judgement of the efficacy and safety of this study; (5) during the treatment, the patients have showed other internal or outernal illness which might affect this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Screening for Somatoform Symptoms-7, SOMS-7;Somatic Self-rating Scale, SSS;Hamilton Anxiety Scale, HAMA;Hamilton Depression Scale, HAMD;Clinical Global Impression, CGI;Treatent Emergent Symptom Seale, TESS;Rating Scale for Side Effects, SERS; | — |
Countries
China
Contacts
Public ContactJin Song
Outcome results
None listed